Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) have earned an average recommendation of “Moderate Buy” from the seventeen analysts that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, fourteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $23.3571.

Several research firms have recently commented on CMPS. Royal Bank Of Canada decreased their target price on Compass Pathways from $22.00 to $21.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. B. Riley Financial boosted their price target on Compass Pathways from $17.00 to $22.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Raymond James Financial reiterated a “buy” rating on shares of Compass Pathways in a research report on Friday, May 22nd. Morgan Stanley boosted their target price on shares of Compass Pathways from $17.00 to $18.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Finally, BTIG Research upped their price target on shares of Compass Pathways from $14.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, July 7th.

Compass Pathways Stock Performance

Shares of CMPS stock opened at $13.27 on Friday. Compass Pathways has a 52 week low of $4.82 and a 52 week high of $15.40. The company has a market capitalization of $1.84 billion, a price-to-earnings ratio of -2.87 and a beta of 2.54. The company has a 50-day simple moving average of $13.10 and a 200 day simple moving average of $10.34. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.30 and a current ratio of 1.30.

Compass Pathways (NASDAQ:CMPS) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($1.88) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($1.49). On average, sell-side analysts predict that Compass Pathways will post -1.26 earnings per share for the current year.

Institutional Trading of Compass Pathways

A number of institutional investors have recently bought and sold shares of CMPS. TD Waterhouse Canada Inc. increased its holdings in shares of Compass Pathways by 4,292.2% during the second quarter. TD Waterhouse Canada Inc. now owns 30,306 shares of the company’s stock worth $402,000 after purchasing an additional 29,616 shares during the period. Ancora Advisors LLC bought a new stake in shares of Compass Pathways in the second quarter valued at approximately $43,000. Seven Fleet Capital Management LP boosted its stake in shares of Compass Pathways by 295.1% in the first quarter. Seven Fleet Capital Management LP now owns 158,021 shares of the company’s stock valued at $874,000 after buying an additional 118,021 shares during the period. Parallel Advisors LLC grew its position in Compass Pathways by 8,450.6% during the first quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock worth $40,000 after buying an additional 7,183 shares in the last quarter. Finally, Vivo Capital LLC acquired a new stake in Compass Pathways during the first quarter worth approximately $1,106,000. Institutional investors own 46.19% of the company’s stock.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.